Heidelberg Epignostix
- Company typePrivate
- Founded2023
- HeadquartersHeidelberg, Germany
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
Heidelberg Epignostix firmographics
Firmographics- Name
- Heidelberg Epignostix
- Legal name
- Heidelberg Epignostix GmbH
- Website
- https://epignostix.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Heidelberg Epignostix industry classification
Industry- Product category
- Molecular Diagnostics Software
- NAICS
- Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Epigenomics & Chromatin Profiling Services (HLAGANAF)
Keywords
Where Heidelberg Epignostix is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Markets served
Heidelberg Epignostix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Heidelberg Epignostix product offering
Product offeringCore offering
Heidelberg Epignostix develops and licenses AI-based DNA methylation classifiers that classify central nervous system (CNS) and sarcoma tumors from methylation array data. Its cloud-hosted Classifier App accepts Illumina 450K/EPIC IDAT files and returns hierarchical classification scores, confidence scores, copy number profiles, and MGMT promoter methylation status predictions. The CNS Tumor Methylation Classifier (Heidelberg Brain Tumor Classifier) and Sarcoma Methylation Classifier are offered free for academic research, with commercial and diagnostic use licensed separately to hospital and reference laboratories.
Product overview
Heidelberg Epignostix offers a single integrated product platform—the Heidelberg Epignostix Research App (Classifier App) at app.epignostix.com—delivered alongside a portfolio of two core AI-based, DNA methylation tumor classifiers: the flagship CNS Tumor Methylation Classifier (Heidelberg Brain Tumor Classifier) and the Sarcoma Methylation Classifier. Both classifiers operate on the same underlying random-forest AI architecture and the same input data format (Illumina Human Methylation 450K / EPIC v1 / EPIC v2 BeadChip IDAT files), and they share a common web portal experience that returns classification scores, confidence scores, copy number profiles, and MGMT promoter methylation status predictions as downloadable PDF reports. The CNS classifier (covering 184 subclasses) is the flagship and is also the basis of the company's IVD-R / CE-mark diagnostic certification push and its proprietary CPT code 0020M for U.S. Medicare reimbursement, while the Sarcoma classifier extends the platform to mesenchymal tumors (covering 120 sub-classes as of mid-2025). On the roadmap sit additional classifiers for other cancer types (e.g., epithelial cancers such as skin cancer) and a Nanopore-sequencing-compatible classifier, all expected to plug into the same portal/AI platform. The classifiers are currently offered Research Use Only for academic research, with clinical/diagnostic use licensed separately to hospital labs.
Differentiator
Problem solved
Functional benefit
Brands
- Heidelberg Brain Tumor Classifier (Heidelberg CNS Tumor Methylation Classifier): Flagship AI-based DNA methylation classifier for central nervous system (CNS) tumor classification; lead commercial product of Heidelberg Epignostix.
- Sarcoma Methylation Classifier
- Heidelberg Epignostix Classifier App
Products and services
- CNS Tumor Methylation Classifier (Heidelberg Brain Tumor Classifier) Flagship AI-based DNA methylation classifier for central nervous system (CNS) tumors, trained on a reference set of 7,495 samples covering 184 CNS tumor subclasses. Uses a random forest ensemble algorithm to compare new methylation profiles against the reference cohort and outputs classification scores at four hierarchy levels (methylation subclass, class, family, superfamily) with confidence scores between 0 and 1.
- Sarcoma Methylation Classifier
Companies that use Heidelberg Epignostix
Customer profileIdeal customer profiles2 records
Heidelberg Epignostix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability5 records
Heidelberg Epignostix partnerships and signals
Strategic signalRecent moves7 records
Expansion highlights6 records
Heidelberg Epignostix competitors and assessment
Company assessmentBroad incumbents
- QIAGEN: Global molecular diagnostics and sample-preparation leader; Epignostix's CEO Helge Lubenow was previously Head of Diagnostics Business at QIAGEN. Overlapping in oncology molecular diagnostics and methylation/PCR-based workflows.
- Foundation Medicine (Roche): Leader in comprehensive genomic profiling for cancer (FoundationOne CDx). Comparable as an AI-enabled molecular oncology diagnostics provider serving clinicians and biopharma, though focused on DNA sequencing rather than methylation arrays.
- Caris Life Sciences: Multi-omics molecular profiling company (MI Profile, Caris Assure) for oncology. Comparable as a broad molecular tumor-classification and therapy-guidance platform, competing for the same oncology diagnostics customer wallet.
- Tempus Labs: AI-enabled precision medicine company combining multi-modal molecular data and clinical records for oncology. Comparable as a data- and AI-driven cancer diagnostics player targeting similar clinical and biopharma customers.
- NeoGenomics: Oncology-focused clinical laboratory services and molecular diagnostics provider. Comparable as a channel through which methylation-based classifiers like Epignostix's could be distributed, and as a competing molecular oncology menu.
- Veracyte: Genomic diagnostics company with proprietary molecular tests across oncology indications. Comparable business model of building a portfolio of AI/molecular tests sold to pathology and oncology clinicians.
Direct peers
- NanoString Technologies (a Bruker company): Provider of spatial genomics and methylation profiling products (nCounter, GeoMx, CosMx). Comparable as a seller of methylation-based molecular profiling tools to research and clinical pathology customers, with overlapping array-based technologies.
Emerging players
- Akoya Biosciences: Spatial biology company offering multiplex profiling (PhenoCycler, PhenoImager). Comparable as a next-generation molecular profiling platform serving translational and clinical research in oncology.
- Paige.AI: AI-based digital pathology and cancer diagnostics company (FDA-authorized prostate cancer AI). Comparable as an AI-first pathology diagnostics company targeting similar clinical oncology use cases and reimbursement pathways.
- PathAI: AI-powered pathology company combining deep learning with histology and biomarker data. Comparable as an AI-driven diagnostics company in oncology with a focus on improving pathologist accuracy and clinical decision support.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Heidelberg Epignostix social profiles
Digital presenceHeidelberg Epignostix compliance and trust
Trust signalCompliance3 records
Heidelberg Epignostix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Heidelberg Epignostix leadership team
Management profileNumber of profiles
Profiles13 records
Heidelberg Epignostix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Heidelberg Epignostix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Heidelberg Epignostix
What does Heidelberg Epignostix do?
Heidelberg Epignostix develops and licenses AI-based DNA methylation classifiers that classify central nervous system (CNS) and sarcoma tumors from methylation array data. Its cloud-hosted Classifier App accepts Illumina 450K/EPIC IDAT files and returns hierarchical classification scores, confidence scores, copy number profiles, and MGMT promoter methylation status predictions. The CNS Tumor Methylation Classifier (Heidelberg Brain Tumor Classifier) and Sarcoma Methylation Classifier are offered free for academic research, with commercial and diagnostic use licensed separately to hospital and reference laboratories.
Is Heidelberg Epignostix a public or private company?
Heidelberg Epignostix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Heidelberg Epignostix founded?
Heidelberg Epignostix was founded in 2023. It employs 11 to 50 people.
Where is Heidelberg Epignostix based?
Heidelberg Epignostix is headquartered in Heidelberg, Germany, in the Europe region.
Who are Heidelberg Epignostix's main competitors?
Broad incumbents on record are QIAGEN, Foundation Medicine (Roche), Caris Life Sciences, Tempus Labs, NeoGenomics and Veracyte. NanoString Technologies (a Bruker company) is listed as a direct peer. Emerging players are Akoya Biosciences, Paige.AI and PathAI.
Does Heidelberg Epignostix have an API?
Yes. Heidelberg Epignostix offers global access to cloud-based API services (AIaaS) for state-of-the-art diagnostics tools. Interested parties are directed to contact [email protected]. The APIs enable programmatic access to the company's methylation-based tumor classification tools. The classifier tool can also be deployed as a local copy installed by medical professionals. Specific details on API type (REST/GraphQL), authentication, rate limits, versioning, and sandbox availability are not specified.
What industry is Heidelberg Epignostix in?
Heidelberg Epignostix's product category is Molecular Diagnostics Software. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 6215 and its SIC code is 8071.